Background rates, and why they matter for attribution
Rapid weight loss by any means raises gallstone risk. Separating that from a direct drug effect requires a comparator, and the trials have one.
Salomé Adeyemi
Page 12 of 13 of this archive, newest first.
Archive — page 12
243 piecesWhat the new Italy guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Germany guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Gallstones during rapid weight loss: drug, or weight loss?
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
The template economy: one certificate, many products
A blank certificate with the numbers left editable is an ordinary internal document. Its circulation as a finished record is the problem.
The interventions with trial support, and the much longer list without
Almost nothing in the standard management repertoire has been tested in a randomised trial in this specific population. We say what is extrapolated and from where.
What the new the United Arab Emirates guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
Specification and result are two columns, and only one of them is a measurement
Statements of conformity are supposed to rest on a stated decision rule. Almost nothing in this trade states one.
What the new Canada guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Turkey guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Resolving power and mass accuracy are two different specifications
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
Albumin, fatty-acid chains, and the engineering that made a weekly incretin possible
The molecular engineering that turned a peptide with a two-minute half-life into a once-weekly drug.
What the new Argentina guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What orthogonal actually means, and what it does not
The most useful single addition to any purity determination is a second separation under a different pH or on a different stationary phase, and the second-most useful is a…
Pancreatitis, obstruction, gallbladder: three things nausea can be
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.